Astrocyte glycogen metabolism is required for neural activity during aglycemia or intense stimulation in mouse white matter.
We tested the hypothesis that inhibiting glycogen degradation accelerates compound action potential (CAP) failure in mouse optic nerve (MON) during aglycemia or high-intensity stimulation. Axon function was assessed as the evoked CAP, and glycogen content was measured biochemically. Isofagomine, a novel inhibitor of central nervous system (CNS) glycogen phosphorylase, significantly increased glycogen content under normoglycemic conditions. When MONs were bathed in artificial cerebrospinal fluid (aCSF) containing 10 mM glucose, the CAP failed 16 min after exposure to glucose-free aCSF. MONs bathed in aCSF plus isofagomine displayed accelerated CAP failure on glucose removal. Similar results were obtained in MONs bathed in 30 mM glucose, which increased baseline glycogen concentration. The ability of isofagomine to increase glycogen content thus was not translated into delayed CAP failure. This is likely due to the inability of the tissue to metabolize glycogen in the presence of isofagomine, highlighting the importance of glycogen in sustaining neural function during aglycemia. The hypothesis that glycogen breakdown supports intense neural activity was tested by blocking glycogen breakdown during periods of high-frequency stimulation. The CAP area declined more rapidly when glycogen metabolism was inhibited by isofagomine, explicitly showing an important physiological role for glycogen metabolism during neural activity.
Brown
Angus M
AM
Department of Neurology, University of Washington, Seattle, WA, USA. ambrown@nottingham.ac.uk
Sickmann
Helle M
HM
Fosgerau
Keld
K
Lund
Trine M
TM
Schousboe
Arne
A
Waagepetersen
Helle S
HS
Ransom
Bruce R
BR
D000200:Action Potentials / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects*; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology*; D004347:Drug Interactions; D004558:Electric Stimulation; D005947:Glucose / Q000172:deficiency / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism*; D024981:Glycogen Phosphorylase / Q000037:antagonists & inhibitors; D006943:Hyperglycemia / Q000503:physiopathology; D007003:Hypoglycemia / Q000378:metabolism* / Q000503:physiopathology; D050112:Imino Pyranoses; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008954:Models, Biological; D009900:Optic Nerve / Q000187:drug effects / Q000503:physiopathology / Q000528:radiation effects; D010100:Oxygen / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects
D050112:Imino Pyranoses; D010880:Piperidines; C098432:isofagomine; D006003:Glycogen; D024981:Glycogen Phosphorylase; D005947:Glucose; D010100:Oxygen